Multimodal treatment strategies in patients undergoing surgery for hepatocellular carcinoma

Digestive Diseases

Volumn 31, Issue 1, 2013, Pages 112-117

  Lurje, Georg ^a   Lesurtel, Mickaël ^a   Clavien, Pierre Alain ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cirrhosis; Liver transplantation; Surgical resection

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONFERENCE PAPER; CRYOABLATION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LOCAL THERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SYSTEMIC THERAPY;

EID: 84879593584     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000347205     Document Type: Conference Paper

References (39)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Clavien PA, Petrowsky H, DeOliveira ML, Graf R: Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-1559.
3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
4. Lin S, Hoffmann K, Schemmer P: Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012; 1: 144-158.
5. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
6. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70.
7. Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 2012; 1: 71-82.
8. Slankamenac K, Breitenstein S, Held U, Beck-Schimmer B, Puhan MA, Clavien PA: Development and validation of a prediction score for postoperative acute renal failure following liver resection. Ann Surg 2009; 250: 720-728.
9. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J: Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234: 63-70.
10. McCormack L, Petrowsky H, Clavien PA: Surgical therapy of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 497-503.
11. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M: One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198-1206, discussion 1206.
12. Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE: Role of liver transplantation in cancer therapy. Ann Surg 1985; 202: 401-407.
13. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
14. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
15. D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, Guido M, del Rio Martin J, Schiano T, Cillo U: Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009; 15: 1278-1287.
16. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11-e22.
17. Lencioni R, Crocetti L: Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol 2007; 10: 38-46.
18. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P: Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-391.
19. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC: Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007; 17: 684-692.
20. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, Vicaut E, Trinchet JC, Sellier N, Beaugrand M, et al: Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-1483.
21. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912.
22. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA: Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644-2650.
23. Yamashita Y, Takahashi M, Fukushima S, Nishida M, Nakano M: Experimental study of hepatic artery embolization: evaluation of various embolic materials. Radiat Med 1987; 5: 75-82.
24. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP, American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, Society for Surgery of the Alimentary Tract: Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 2010; 12: 313-320.
25. Kennedy AS, Salem R: Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010; 16: 163-175.
26. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, van Het Schip AD, Nijsen JF: Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured metaanalysis. Eur Radiol 2009; 19: 951-959.
27. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS: Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 224-230.
28. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, et al: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterology 2010; 138: 52-64.
29. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, Shaked A, Furth E, Reddy KR, Olthoff K: Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665-673.
30. Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, et al: Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005; 11: 1117-1126.
31. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, et al: Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49: 1185-1193.
32. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchiano A, et al: Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909.
33. Majno PE, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D: Is treatment of HCC on the waiting list necessary? Liver Transpl 2011; 17(Suppl 2):S98-S108.
34. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, et al: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738-746.
35. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, et al: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903.
36. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
37. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160.
38. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
39. National Comprehensive Cancer Network. NCCN Hepatobiliary Cancers Clinical Practice Guidelines in Oncology (Version 2.2008). http://www.nccn.org/professionals/physician-gls/PDF/hepatobiliary.pdf.